LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated…
TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce that…
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post…
-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI…
- Expands Corporate Clinic Opportunity in the Northeast Region - SCOTTSDALE, Ariz., March 23, 2022 (GLOBE NEWSWIRE) -- The Joint…
The randomized cross-over clinical trial assessed the new Provox® Life™ System for pulmonary rehabilitation and quality of life after total…
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an…
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was…
Compositions and Methods for Enhancing Anti-Viral TherapiesCALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the…
Basel, 23 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation of additional medicines and diagnostics…